Diagnosis and management of nonfunctioning pituitary tumors

Annual Review of Medicine

Volumn 47, Issue , 1996, Pages 95-106

  Greenman, Yona ^a   Melmed, Shlomo ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Fsh; Glycoprotein hormone; Lh; Pituitary adenoma; Transsphenoidal surgery

Indexed keywords

DOPAMINE RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GONADOTROPIN; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR;

BRAIN SCINTISCANNING; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; HORMONE RELEASE; HUMAN; HYPOPHYSIS TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REVIEW;

ADENOMA; DIAGNOSIS, DIFFERENTIAL; DIAGNOSTIC IMAGING; HORMONES, ECTOPIC; HUMANS; PARANEOPLASTIC ENDOCRINE SYNDROMES; PITUITARY NEOPLASMS; PROGNOSIS;

EID: 0029986866     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.47.1.95     Document Type: Review

References (51)

1. Reichlin S. 1991. Pathogenesis of pituitary tumors. In Pituitary Adenomas: New Trends in Basic and Clinical Research, ed. G Faglia, P Beck-Peccoz, B Ambrozi, P Travaglini, A Spada, pp. 113-21. Amsterdam: Elsevier Sci.
2. Herman V, Fagin J, Gonski R, et al. 1990. Clonal origin of pituitary adenomas. J. Clin. Endocrinol. Metab. 71:1427-33
3. Alexander JM, Biller BM, Bikkal H, et al. 1990. Clinically nonfunctioning pituitary tumors are monoclonal in origin. J. Clin. Invest. 86:336-40
4. Tordjman K, Stern N, Ouaknine G, et al. 1993. Activating mutations of the Gsα-gene in nonfunctioning pituitary tumors. J. Clin. Endocrinol. Metab. 77:765-69
5. Pei L, Melmed S, Scheithauer B, et al. 1995. Frequent loss of heterozygosity at the retinoblastoma susceptibility gene (RB) locus in aggressive pituitary tumors: evidence for a chromosome 13 tumor supressor gene other than RB. Cancer Res. 55: 1613-16
6. Djerassi A, Coutifaris C, West VA, et al. 1995. Gonadotroph adenoma in a premenopausal woman secreting follicle-stimulating hormone and causing ovarian hyperstimulation. J. Clin. Endocrinol. Metab. 80:591-94
7. Zarate A, Fonseca ME, Mason M, et al. 1986. Gonadotropin-secreting pituitary adenoma with concomitant hypersecretion of testosterone and elevated sperm count. Treatment with LRH agonist. Acta Endocrinol. 113:29-34
8. Faggiano M, Criscuolo T, Perrone I, et al. 1983. Sexual precocity in a boy due to hypersecretion of LH and prolactin by a pituitary adenoma. Acta Endocrinol. 102: 167-72
9. Abrosi B, Basstti M, Ferrario R, et al. 1990. Precocious puberty in a boy with a PRL-, LH- and FSH-secreting pituitary tumour: biosynthetic characterization and clinical studies. Acta Endocrinol. 122: 569-76
10. Katznelson L, Alexander JM, Klibanski A. 1993. Clinically nonfunctioning pituitary adenomas. J. Clin. Endocrinol. Metab. 76: 1089-94
11. Daneshdoost L, Gennarelli TA, Bashey HM, et al. 1993. Identification of gonadotroph adenomas in men with clinically nonfunctioning adenomas by the luteinizing hormone β subunit response to thyrotropin-releasing hormone. J. Clin. Endocrinol. Metab. 77:1352-55
12. Snyder PJ, Bashey H, Phillips JL, et al. 1985. Comparison of hormonal secretory behavior of gonadotroph cell adenomas in vivo and in culture. J. Clin. Endocrinol. Metab. 61:1061-65
13. Daneshdoost L, Gennarelli TA, Bashey HM, et al. 1991. Recognition of gonadotroph adenomas in women. N. Engl. J. Med. 324:589-94
14. Stern N, Tordjman K, Trostanetski Y, et al. 1995. Nonfunctioning pituitary microadenomas secrete β-glycoprotein hormone subunits: evidence that nonfunctioning micro- and macroadenomas originate in a similar cell type. Proc. 77th Annu. Meet. Endocrine Soc., p. 52 (Abstr.)
15. Snyder PJ. 1995. Extensive personal experience: gonadotroph adenomas. J. Clin. Endocrinol. Metab. 80:1059-61
16. Maroldo TV, Dillon WP, Wilson CB. 1992. Advances in diagnostic techniques of pituitary tumors and prolactinomas. Curr. Opin. Oncol. 4:105-15
17. Ur E, Mather SJ, Bomanji J, et al. 1992. Pituitary imaging using a labeled somatostatin analog in acromegaly. Clin. Endocrinol. 36:147-50
18. Greenman Y, Melmed S. 1994. Heterogeneous expression of two somatostatin receptor subtypes in pituitary tumors. J. Clin. Endocrinol. Metab. 78:398-403
19. Miller GM, Alexander JM, Bikkal HA, et al. 1995. Somatostatin receptor subtype gene expression in pituitary adenomas. J. Clin. Endocrinol. Metab. 80:1386-92
20. Faglia G, Bazzoni N, Spada A, et al. 1991. In vivo detection of somatostatin receptors in patients with functionless pituitary adenomas by means of a radioiodinated analog of somatostatin ([123 I] SDZ 204-090). J. Clin. Endocrinol. Metab. 73:850-56
21. de Bruin TWA, Kwekkeboom DJ, Verlaat JWV, et al. 1992. Clinically nonfunctioning pituitary adenoma and octreotide response to long term high dose treatment, and studies in vitro. J. Clin. Endocrinol. Metab. 75:1310-17
22. Plöckinger U, Reichel M, Fett U, et al. 1994. Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy. J. Clin. Endocrinol. Metab. 79:1416-23
23. Verhoeff NPLG, Bemelman FJ, Wiersinga WM, van Royen EA. 1993. Imaging of dopamine D2 and somatostatin receptors in vivo using single-pholon emission tomography in a patient with a TSH/PRL-producing pituitary macroadenoma. Eur. J. Nucl. Med. 20:555-61
24. Pirker W, Brucke T, Riedl M, et al. 1994. Iodine-123-IBZM-SPECT: studies in 15 patients with pituitary tumors. J. Neurotrans. 97:235-44
25. Bevan JS, Burke CW. 1986. Non-functioning pituitary adenomas do not regress during bromocriptine therapy but possess membrane-bound dopamine receptors which bind bromocriptine. Clin. Endocrinol 25:561-72
26. Bevan JS, Webster J, Burke CW, Scanlon MF. 1992. Dopamine agonists and pituitary tumor shrinkage. Endocrine Rev. 13: 220-40
27. Kovacs K, Horvath E, Ryan N, Ezrin C. 1980. Null cell adenoma of the human pituitary. Virchows Arch. A 387:165-74
28. Kontogeorgos G, Kovacs K, Horvath E, Scheithauer BW. 1993. Null cell adenomas, oncocytomas, and gonadotroph adenomas of the human pituitary: an immunocytochemical and ultrastructural analysis of 300 cases. Endocrinol. Pathol. 4: 20-27
29. Asa SL, Cheng Z, Ramyar L, et al. 1992. Human pituitary null cell adenomas and oncocytomas in vitro: effects of adenohypophysiotropic hormones and gonadal steroids on hormone secretion and tumor cell morphology. J. Clin. Endocrinol. Metab. 74:1128-34
30. Kovacs K, Lloyd R, Horvath E, et al. 1989. Silent somatotroph adenomas of the human pituitary. Am. J. Pathol. 134:345-53
31. Kovacs K, Horvath E, Bailey TA, et al. 1978. Silent corticotroph cell adenoma with lysosomal accumulation and crinophagy. Am. J. Med. 64:492-99
32. Molitch ME, Russel EJ. 1990. The pituitary "incidentaloma." Ann. Intern Med. 112: 925-31
33. Teramoto A, Hirakawa K, Sanno N, Osamura Y. 1994. Incidental pituitary lesions in 1000 unselected autopsy specimens. Radiology 193:161-64
34. Hall WA, Luciano MG, Doppman JL, et al. 1994. Pituitary magnetic resonance imaging in normal human volunteers: occult adenomas in the general population. Ann. Intern Med. 120:817-20
35. Molitch ME. 1995. Evaluation and treatment of the patient with a pituitary incidentaloma. J. Clin. Endocrinol. Metab. 80: 3-6
36. Melen O. 1987. Neuro-ophthalmologic features of pituitary tumors. Endocrinol. Metab. Clin. N. Am. 16:585-608
37. Comtois R, Beauregard H, Somma M, et al. 1991. The clinical and endocrine outcome of trans-sphenoidal microsurgery of nonsecreting pituitary adenomas. Cancer 68:860-66
38. Arafah B. 1986. Reversible hypopituitarism in patients with large nonfunctioning pituitary tumors. J. Clin. Endocrinol. Metab. 62:1173-79
39. Greenman Y, Tordjman K, Kisch E, et al. 1995. Relative sparing anterior pituitary function in patients with growth hormone-secreting macroadenomas: comparison with nonfunctioning macroadenomas. J. Clin. Endocrinol. Metab. 80:1577-83
40. Harris RI, Schatz NJ, Gennarelli T, et al. 1983. Follicle-stimulating hormone-secreting pituitary adenomas: correlation of reduction of adenoma size with reduction of hormonal hypersecretion after transsphenoidal surgery. J. Clin. Endocrinol. Metab. 56:1288-93
41. Cozzi R, Orlandi P, Dallabonzana D, et al. 1994. Medical treatment of pituitary adenomas. Front. Endocrinol. 9:191-200
42. Kwekkeboom DJ, De Jong FH, Lamberts SWJ. 1989. Gonadotropin release by clinically nonfunctioning and gonadotroph pituitary adenomas in vivo and in vitro: relation to sex and effects of thyrotropin-releasing hormone, gonadotropin-releasing hormone and bromocriptine. J. Clin. Endocrinol. Metab. 68:1128-35
43. Berezin M, Olchovsky D, Pines A, et al. 1984. Reduction of follicle-stimulating hormone (FSH) secretion in FSH-producing pituitary adenoma by bromocriptine. J. Clin. Endocrinol. Metab. 59:1220-22
44. Klibanski A, Deutsch PJ, Jameson JL, et al. 1987. Luteinizinghormone-secreting pituitary tumor: biosynthetic characterization and clinical studies. J. Clin. Endocrinol. Metab. 64:536-42
45. Klibanski A, Alexander JM, Bikkal HA, et al. 1991. Somatostatin regulation of glycoprotein hormone and free subunit secretion in clinically nonfunctioning and somatotroph adenomas in vitro. J. Clin. Endocrinol. Metab. 73:1248-55
46. Katznelson L, Oppenheim DS, Coughlin JF, et al. 1992. Chronic somatostatin analog administration in patients with α-subunit-secreting pituitary tumors. J. Clin. Endocrinol. Metab. 75:1318-25
47. Mansfield JM, Beardsworth DE. Loughlin JS, et al. 1983. Long-term treatment of central precocious puberty with a long-acting analogue of luteinizing hormone-releasing hormone: effects on somatic growth and skeletal maturation. N. Engl. J. Med. 309:1286-90
48. Klibanski A, Jameson JL, Biller BMK, et al. 1989. Gonadotropin and α-subunit responses to chronic gonadotropin-releasing hormone analog administration in patients with glycoprotein hormone-secreting pituitary tumors. J. Clin. Endocrinol. Metab. 68:81-86
49. Snyder PJ. 1995. Gonadotroph adenomas. In The Pituitary, ed. S Melmed, pp. 559-75. Cambridge, MA: Blackwell Sci.
50. Alexander JM, Klibanski A. 1994. Gona dotropin-releasing hormone receptor mRNA expression by human pituitary tumors in vitro. J. Clin. Invest. 93:2332-39
51. McGrath GA, Gonçalves RJ, Udupa JK, et al. 1993. New technique for quantitation of pituitary adenoma size: use in evaluating treatment of gonadotroph adenomas with a gonadotropin-releasing hormone antagonist. J. Clin. Endocrinol. Metab. 76: 1363-68